The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTNI8054903]

BMC Clinical Pharmacology

Volumn 3, Issue , 2003, Pages

  Mills, Edward ^a,b   Prousky, Jonathan ^a   Raskin, Gannady ^c   Gagnier, Joel ^d   Rachlis, Beth ^a   Montori, Victor M ^e   Juurlink, David ^f  

^a CANADIAN COLLEGE OF NATUROPATHIC MEDICINE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c BASTYR UNIVERSITY   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Niacin; Over the counter; Randomized controlled trial

Indexed keywords

NICOTINIC ACID; NON PRESCRIPTION DRUG; PLACEBO; ANTILIPEMIC AGENT;

ADULT; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG RELEASE; DRUG SAFETY; DYSPNEA; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; INCIDENCE; MALE; NAUSEA; NORMAL HUMAN; OUTCOMES RESEARCH; PATIENT COUNSELING; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SIDE EFFECT; SKIN TINGLING; STOMACH SPASM; TABLET FORMULATION; VERTIGO; VOLUNTEER; VOMITING; CHEMICALLY INDUCED DISORDER; DOUBLE BLIND PROCEDURE; GASTROINTESTINAL DISEASE; MIDDLE AGED; SAFETY;

ADULT; DOUBLE-BLIND METHOD; FEMALE; FLUSHING; GASTROINTESTINAL DISEASES; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; NIACIN; PLACEBOS; SAFETY;

EID: 2942545910     PISSN: 14726904     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-3-4     Document Type: Article

References (23)

1. FDA: . Center for Food Safety & Applied Nutrition. Dietary Supplements [http://vm.cfsan.fda.gov/~dms/supplmnt.html]. Dec. 10, 2002
2. HealthCanada.: Dept of Justice. Food and Drugs Act. ( R.S. 1985, c. F-27 ) .
3. Barnes J, Mills SY, Abbot NC, Willoughby M and Ernst E: Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998, 45:496-500.
4. Eland IA, Belton KJ, van Grootheest AC, Meiners AP, Rawlins MD and Stricker BH: Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol 1999, 48:623-627.
5. Improving ADR reporting. Lancet 2002, 360:1435.
6. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ and Friedewald W: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
7. Kashyap ML, McGovern ME, Berra K, Guyton JR, Kwiterovich PO, Harper WL, Toth PD, Favrot LK, Kerzner B, Nash SD, Bays HE and Simmons PD: Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002, 89:672-678.
8. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J and Albers JJ: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
9. SoRelle R: Niacin-simvastatin combination benefits patients with coronary artery disease. Circulation 2001, 104:E9050-60.
10. Morrow JD, Parsons W. G., 3rd and Roberts L. J., 2nd: Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989, 38:263-274.
11. Morrow JD, Awad JA, Oates JA and Roberts L. J., 2nd: Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol 1992, 98:812-815.
12. Jungnickel PW, Maloley PA, Vander Tuin EL, Peddicord TE and Campbell JR: Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 1997, 12:591-596.
13. Dunn RT, Ford MA, Rindone JP and Kwiecinski FA: Low-Dose Aspirin and Ibuprofen Reduce the Cutaneous Reactions Following Niacin Administration. Am J Ther 1995, 2:478-480.
14. McKenney JM, Proctor JD, Harris S and Chinchili VM: A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. Jama 1994, 271:672-677.
15. Clementz GL and Holmes AW: Nicotinic acid-induced fulminant hepatic failure. J Clin Gastroenterol 1987, 9:582-584.
16. Ernst E and Pittler MH: Risks associated with herbal medicinal products. Wien Med Wochenschr 2002, 152:183-189.
17. Aronson JK, Derry S and Loke YK: Adverse drug reactions: keeping up to date. Fundam Clin Pharmacol 2002, 16:49-56.
18. Bracchi R: Drug companies should report side effects in terms of frequency. Bmj 1996, 312:442.
19. Edwards JE, McQuay HJ, Moore RA and Collins SL: Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. J Pain Symptom Manage 1999, 18:427-437.
20. Derry S, Kong Loke Y and Aronson JK: Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol 2001, 1:7.
21. Figueiras A, Tato F, Fontainas J, Takkouche B and Gestal-Otero JJ: Physicians' attitudes towards voluntary reporting of adverse drug events. J Eval Clin Pract 2001, 7:347-354.
22. Yim BT and Chong PH: Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia. Ann Pharmacother 2003, 37:106-115.
23. Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG and Cressman MD: Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 2003, 91:1304-1310.